Elidel (Pimecrolimus) Cream - Uses, Dose, Side effects, MOA, Brands

Elidel (Pimecrolimus) is a calcineurin inhibitor for topical application. It inhibits the activation of T-cells in the epidermis of the skin when applied topically.

Elidel (Pimecrolimus) Uses:

  • Atopic dermatitis:
    • It is recommended as a second-line therapy for the short-term continuous treatment or long-term non-continuous treatment of mild to moderate atopic dermatitis in non-immuno-compromised patients older than 2 years of age who have not responded to other topical treatments or when other treatments are not possible.
  • Use: Off-Label: Adult
    • Oral lichen planus
    • Vitiligo
    • Intertriginous and facial psoriasis

Other calcineurin inhibitors include: Tacrolimus, sirolimus, temsirolimus, and everolimus

Elidel (Pimecrolimus) Dose in  Adults

Elidel (Pimecrolimus) Dose in the treatment of mild to moderate Atopic dermatitis:

  • Apply a small coating twice a day to the afflicted region.
  • Just apply the medication to the afflicted regions.
  • As soon as the symptoms disappear, stop the medication.
  • If no progress is shown after six weeks of therapy, reassess and reevaluate the patient.

Elidel (Pimecrolimus) Dose in the treatment of oral lichen planus (off-label):

  • Apply over the affected area twice daily for one month.

Elidel (Pimecrolimus) Dose in the treatment of Psoriasis (off-label):

  • Apply twice daily over the affected area.

Elidel (Pimecrolimus) Dose in the treatment of Vitiligo (off-label):

  • Apply for six months, twice each day.
  • Although a 12-month course of therapy could be beneficial, the drug's long-term safety has not been shown.

Elidel (Pimecrolimus) Dose in Childrens

Elidel (Pimecrolimus) Dose in the treatment of mild to moderate atopic dermatitis:

  • Children over 2 years and Adolescents:
    • Apply topically twice a day in a thin coating over the afflicted region.
    • Ensure that you only apply to the impacted region.
    • If after six weeks of therapy there is still no sign of change, re-evaluate and re-assess the patient.
    • When the symptoms go away, stop.

Pregnancy Risk Factor C

  • The topical application of topical creams did not cause adverse reactions in animal reproduction studies.

Pimecrolimus use during breastfeeding:

  • It is unknown if the drug will be excreted into breastmilk.
  • Manufacturers recommend that you stop breastfeeding, or that you use the drug. This is based on the risk and benefits of drug-exposure to your infant.

Elidel (Pimecrolimus) dose in kidney disease:

The manufacturer has not recommended any adjustments in the dose in patients with renal disease.   

Elidel (Pimecrolimus) dose in liver impairment:

The manufacturer has not recommended any adjustments in the dose in patients with liver disease.   

Common Side Effects of Elidel (Pimecrolimus):

  • Central Nervous System:
    • Headache
    • Fever
  • Infection:
    • Influenza
  • Local:
    • Local Burning
    • Application Site Reaction
  • Respiratory:
    • Nasopharyngitis
    • Upper Respiratory Tract Infection
    • Cough
    • Bronchitis

Less Common Side Effects Of Elidel (Pimecrolimus):

  • Dermatologic:
    • Acne Vulgaris
    • Herpes Simplex Dermatitis
    • Folliculitis
    • Skin Infection
    • Impetigo
    • Warts
    • Molluscum Contagiosum
    • Urticaria
  • Gastrointestinal:
    • Constipation
    • Abdominal Pain
    • Diarrhea
    • Gastroenteritis
    • Vomiting
    • Toothache
    • Nausea
  • Infection:
    • Staphylococcal Infection
    • Varicella
    • Viral Infection
    • Herpes Simplex Infection
    • Bacterial Infection
  • Genitourinary:
    • Dysmenorrhea
  • Hypersensitivity:
    • Hypersensitivity
  • Local:
    • Local Irritation
    • Local Pruritus
    • Localized Erythema
  • Neuromuscular & Skeletal:
    • Arthralgia
    • Back Pain
  • Otic:
    • Otic Infection
    • Otitis Media
  • Ocular:
    • Conjunctivitis
    • Eye Infection
  • Respiratory:
    • Sore Throat
    • Pharyngitis
    • Tonsillitis
    • Asthma
    • Asthma Aggravated
    • Streptococcal Pharyngitis
    • Nasal Congestion
    • Sinusitis
    • Epistaxis
    • Dyspnea
    • Flu-Like Symptoms
    • Pneumonia
    • Rhinitis
    • Rhinorrhea
    • Viral Upper Respiratory Tract Infection
    • Wheezing
  • Miscellaneous:
    • Laceration

Contraindications to Elidel (Pimecrolimus):

Allergy or sensitivity to pimecrolimus, any component of the formulation

Warnings and precautions

  • Infection
    • Patients with atopic dermatology are at greater risk for skin infections. Pimecrolimus, which can also be used to treat atopic dermatitis, may increase the likelihood of skin infections like varicella-zoster and eczema.
    • Treat the local infection first before beginning medication.
    • Do not apply the medication to locations where there are active viral and bacterial illnesses.
  • Local symptoms
    • In the first few days, local symptoms like burning, pruritus and stinging can be resolved by self-treatment. These symptoms may resolve as the lesions heal.
  • Lymphadenopathy:
    • It could be linked to lymphadenopathy. If lymphadenopathy is suspected, it is important to investigate infectious causes immediately.
    • Patients with infectious mononucleosis and patients suffering from lymphadenopathy may have to stop receiving treatment.
  • Malignancy: [US Boxed Warning]
    • Patients with premalignant or malignant skin conditions, such as cutaneous T cell lymphoma, should not be given pimecrolimus or other calcineurin inhibitors.
    • Rare cases of skin cancers and lymphomas have been linked to its use.
  • Skin papilloma
    • Pimecrolimus treatment may lead to the worsening or development of skin papilloma.
    • If the condition is getting worse or the papillomas are not responding to standard treatment, discontinue the treatment.
  • Atopic dermatitis:
    • If clinical improvement does not occur within six weeks after treatment, discontinue the use of the product.
  • Erythroderma
    • Pimecrolimus safety has not been proven safe in patients with generalized acne. Avoid using it.
  • Systemic absorption may be increased by skin diseases
    • It should not be used by anyone who has Netherton's syndrome or any other skin problems.

Pimecrolimus: Drug Interaction

Risk Factor C (Monitor therapy)

CYP3A4 Inhibitors (Moderate)

Pimecrolimus's metabolism could be slowed down. Exceptions: Citrus Juice. Risk C: Follow-up treatment

CYP3A4 Inhibitors (Strong)

Pimecrolimus's metabolism could be slowed down. Risk C: Follow-up treatment

Risk Factor X (Avoid combination)

Immunosuppressants

Immunosuppressants' harmful or hazardous effects may be increased by pimecrolimus. Cytarabine is an exception (Liposomal).

Monitor:

  • Monitor the response to therapy.
  • Re-evaluate if no improvement is noted within six weeks of the treatment.   

How to administer Elidel (Pimecrolimus)?

  • Wash hands before and after applying for the medicine.
  • A thin layer should be applied to the affected skin.
  • Apply only to the area affected. Avoid applying occlusive dressings.
  • Treatment with pimecrolimus may cause a burning sensation initially that improves when the condition starts to settle.
  • If the symptoms persist beyond six weeks, re-evaluate the patient.
  • Moisturizers may be applied over the area.

Oral lichen planus:

  • To the oral mucosa that is impacted, use pimecrolimus.
  • In order to prevent the medication from being diluted by saliva, cover it with a thin layer of gauze.
  • After applying the medication, wait at least 30 minutes before eating, chewing, or drinking anything.

Mechanism of action of Elidel (Pimecrolimus):

  • Pimecrolimus blocks the activation of T-cells in epidermis by inhibiting transcription of T-cell activating proinflammatory cytokine gene genes like IL-2, IL-4 and IL-10. It inhibits calcineurin binding to intracellular protein FKBP-12.
  • This blocks the transcription of cytokines, and inhibits T cell activation.
  • When stimulated with antigens/ IgE, it also stops the release of inflammatory mediators from mast cells.

The beginning of action:

  • For significant improvements to be seen, it takes around eight days.

Absorption:

  • It is very absorbent when applied topically.
  • The drug was administered to treat atopic dermatitis and the blood concentration was not more than 2 ng/ml, despite the fact that the drug had a body surface area of 13-62 percent.
  • Because of the large body surface area and high body mass, blood concentrations can be higher in pediatric patients.

Protein binding:

  • The majority of the drug's 99.5% protein binding is to lipoproteins.

Metabolism:

  • It is metabolized by the liver via cytochrome (CYP) P450 3A4

Excretion:

  • Feces (78.4% as metabolites; <1% as unchanged drug)

Half-life elimination:

  • Terminal half-life after oral administration is about 30 to 40 hours.

Time to peak serum concentration when applied topically:

  • two to six hours

International Brands of Pimecrolimus:

  • Elidel
  • Pimecroderm
  • Pimoroyal

Pimecrolimus Brand Names in Pakistan:

No Brands Available in Pakistan.  

Comments

NO Comments Found